¼¼°èÀÇ ½ÉÀå ÆÇ¸·Àý°³µµ ½ÃÀå
Cardiac Valvulotome
»óǰÄÚµå : 1731982
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÉÀå ÆÇ¸·Àý°³µµ ½ÃÀåÀº 2030³â±îÁö 1¾ï 4,100¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 1,500¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ½ÉÀå ÆÇ¸·Àý°³µµ ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 4,100¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ È®Àå °¡´É ½ÉÀå ÆÇ¸·Àý°³µµ´Â CAGR 4.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8,940¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Over the Wire ½ÉÀå ÆÇ¸·Àý°³µµºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,130¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÉÀå ÆÇ¸·Àý°³µµ ½ÃÀåÀº 2024³â¿¡ 3,130¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2,840¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.3%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½ÉÀå ÆÇ¸·Àý°³µµ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÉÀå ÆÇ¸· ±â°è´Â ¿Ö ½ÉÀå ÆÇ¸·ÁõÀÇ ¿Ü°úÀû °ü¸®¿¡¼­ ´Ù½Ã±Ý Á߿伺ÀÌ ³ô¾ÆÁö°í Àִ°¡?

½ÉÀå ÆÇ¸·±â±¸´Â ÁÖ·Î ÆÇ¸· Àý°³¼úÀ̳ª ÆÇ¸· ¼ºÇü¼ú¿¡¼­ À¯ÂøµÇ°Å³ª µÎ²¨¿öÁø ½ÉÀå ÆÇ¸·À» ÀýÁ¦Çϰųª Àý°³ÇÏ´Â µ¥ »ç¿ëµÇ´Â Áß¿äÇÑ ¼ö¼ú±â±¸ÀÔ´Ï´Ù. ÀÌ ±â±¸´Â ·ù¸¶Æ¼½º¼º ¶Ç´Â ¼±Ãµ¼º ÆÇ¸·Áõ ÇùÂøÁõ Ä¡·á¿¡ °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ¸ç, ÆÇ¸·À» ¿ÏÀüÈ÷ ±³Ã¼ÇÏÁö ¾Ê°í ÆÇ¸· ±â´ÉÀ» ȸº¹½ÃŰ´Â °ÍÀÌ ÀÓ»óÀûÀ¸·Î À¯¸®ÇÕ´Ï´Ù. Àü ¼¼°è¿¡¼­ ½ÉÇ÷°ü Áúȯ Áõ°¡, ƯÈ÷ ·ù¸¶Æ¼½º¼º ½ÉÀ庴(RHD)ÀÌ ¿©ÀüÈ÷ À¯ÇàÇϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ ½ÉÀå ÆÇ¸· ±â±â´Â ¿Ü°úÀû Ä¡·á¿¡¼­ ´Ù½Ã ÇÑ ¹ø Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù.

ƯÈ÷ ½Â¸ðÆÇ¸· ÇùÂøÁõ¿¡¼­ ±× À¯¿ë¼ºÀÌ µÎµå·¯Áö¸ç, ÀþÀº ȯÀÚ³ª °æÇÇÀû Ä«Å×ÅÍ ÆÇ¸· ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­ ¸¹ÀÌ »ç¿ëµË´Ï´Ù. ¿ø·¡ÀÇ ÆÇ¸· ±¸Á¶¸¦ º¸Á¸Çϰí Ç÷ÇൿÅÂÀû ±â´ÉÀ» À¯ÁöÇÔÀ¸·Î½á ÆÇ¸· ġȯ¼úº¸´Ù ÆÇ¸· º¹¿ø¼úÀ» ¿ì¼±½ÃÇÏ´Â °³½É¼ú ¼¾ÅÍ¿¡ ÀÖÀ¸¸ç, ÆÇ¸· ¿ë±â¸¦ »ç¿ëÇÏ´Â °ÍÀº ½ÇÇà °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ƯÁ¤ ȯÀÚ±º¿¡¼­ ´õ ³ªÀº Àå±âÀû °á°ú¿Í Àΰø ÆÇ¸· ÇÕº´Áõ °¨¼Ò¸¦ Áö¿øÇÕ´Ï´Ù.

±â±âÀÇ °³¼±°ú ¼ö¼úÀÇ ¹ßÀüÀ¸·Î ¹ëºä·ÎÅèÀÇ Á¤È®µµ¿Í ÀÓ»ó °á°ú´Â ¾î¶»°Ô Çâ»óµÇ°í Àִ°¡?

¹ëºêºä·ÎÅè ¼³°èÀÇ ¹ßÀüÀº ¼ö¼úÀû Á¦¾î, Á¤È®¼º ¹× ÇØºÎÇÐÀû ÀûÀÀ¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. Ãֽбâ±â´Â ³¯Ä«·Ó°Ô ¿¬¸¶µÈ ¹Ì¼¼ÇÑ ºí·¹À̵å, °­È­µÈ ±×¸³ ÀÎü°øÇÐ, ´Ù¾çÇÑ ÆÇ¸· ÇüÅ¿¡ ¸Â´Â °¡º¯Àû Å©±â µîÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. ½ÅÃ༺ ÀÖ´Â ºí·¹ÀÌµå ±¸¼º°ú °°Àº ±â¼ú Çõ½ÅÀ¸·Î ÁÖº¯ ½ÉÀå Á¶Á÷¿¡ ´ëÇÑ ¿Ü»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 º¸´Ù Á¤¹ÐÇÑ ÆÇ¸· ÀýÁ¦¼úÀÌ °¡´ÉÇÕ´Ï´Ù.

ÃÖ¼Òħ½ÀÀû ½ÉÀå¼ö¼ú(MICS) ±â¼úÀº ¼ö¼ú Áß ¿µ»ó Áø´Ü ¹× ÆÇ¸· ¸ÅÇÎÀÇ °³¼±°ú ÇÔ²² ÆÇ¸· º¸Á¸ ¼ö¼ú¿¡¼­ ÆÇ¸· ºÐ¸®±â »ç¿ëÀÇ Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Á¶±â ÆÇ¸·Áõ ȯÀÚ³ª ÀΰøÆÇ¸· À̽ÄÀÌ ±Ý±âÀΠȯÀÚ¿¡¼­ º¸´Ù º¸Á¸ÀûÀÎ ¼ö¼úÀû Á¢±Ù¹ýÀ» ÁöÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÏÀ̺긮µå ¼ö¼ú½ÇÀÇ º¸±ÞÀ¸·Î ÆÇ¸· ºÐ¸®±â¿Í °°Àº ¼ö¼ú ±â±¸¿Í ½Ç½Ã°£ °æ½Äµµ ½ÉÃÊÀ½ÆÄ(TEE) ¹× Åõ½Ã ¾È³»¸¦ ´õ Àß ÅëÇÕÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½ÉÀåÆÇ¸·±â±â ¼ö¿ä´Â ¾îµð¿¡ ÁýÁߵǾî ÀÖÀ¸¸ç, ¾î¶² ȯÀÚ Áý´ÜÀÌ »ç¿ëÀ» ÃËÁøÇϴ°¡?

¼ö¿ä°¡ °¡Àå ³ôÀº Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«·Î, RHD À¯º´·üÀÌ ¿©ÀüÈ÷ ³ô°í °í±Þ °æÇÇÀû Ä«Å×ÅÍ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ´Â Áö¿ªÀÔ´Ï´Ù. Àεµ, »çÇ϶ó À̳² ¾ÆÇÁ¸®Ä«, µ¿³²¾Æ½Ã¾Æ, ³²¹Ì ÀϺΠÁö¿ªÀº ÆÇ¸· º¸Á¸ Àü·«ÀÇ ÇýÅÃÀ» ¹Þ´Â ÀþÀº RHD ȯÀÚ¿¡¼­ °³½É¼úÀÌ º¸ÆíÈ­µÇ¾î ÀÖ´Â ÁÖ¿ä ½ÃÀåÀÔ´Ï´Ù.

ȯÀÚ±º¿¡´Â ÁÖ·Î ·ù¸¶Æ¼½º¼º ½Â¸ðÆÇ¸· ÇùÂøÁõ, ¼±Ãµ¼º ÆÇ¸· ÀÌ»ó, ¼®È¸ Ä§Âø¼º ÁúȯÀ¸·Î ÆÇ¸· À¯ÇÕÀÌ ¿Ü°úÀûÀ¸·Î ±³Á¤ °¡´ÉÇÑ È¯ÀÚ°¡ Æ÷ÇԵ˴ϴÙ. ¼Ò¾Æ ¹× û¼Ò³â ½ÉÀå ¼ö¼ú ÇÁ·Î±×·¥ ¶ÇÇÑ ÀÛÀº ÇØºÎÇÐÀû ±¸Á¶¿¡ ¸Â´Â Á¤¹ÐÇÑ ÆÇ¸··ÎÅè ±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼±Áø±¹ ½ÃÀåÀÇ ÀϺΠ3Â÷ ÀÇ·á ¼¾ÅÍ¿¡¼­´Â ÀΰøÆÇ¸· À̽ĺ¸´Ù ³»±¸¼ºÀÌ ¶Ù¾î³­ ¼öº¹¹°ÀÌ ÇÊ¿äÇÑ °æ¿ì, ƯÈ÷ ÀúÀ§Çè ¼ö¼ú Èĺ¸ ¹× ÆÇ¸· º¸Á¸ ÇÁ·ÎÅäÄÝ¿¡¼­ ¿©ÀüÈ÷ ÆÇ¸··ÎÅèÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù.

Àü ¼¼°è ½ÉÀå ÆÇ¸· ·ÎÅè ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

½ÉÀåÆÇ¸·Áõ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÀåÆÇ¸·ÁõÀÇ Áö¼ÓÀûÀÎ ºÎ´ã, ÆÇ¸· º¸Á¸ ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ, ½ÅÈï ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ºñ¿ë È¿À²ÀûÀÎ ½ÉÇ÷°ü Åø¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¿¡ ±âÀÎÇÕ´Ï´Ù. ·ù¸¶Æ¼½º¼º ½ÉÀåÁúȯÀº ¿©ÀüÈ÷ Àü ¼¼°è ÆÇ¸·Áõ ¼ö¼úÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î, ÆÇ¸· ±â±â´Â ½ÉÀå ¿Ü°ú ÀÇ»çÀÇ ÇʼöÀûÀÎ Àåºñ·Î ³²¾ÆÀÖ½À´Ï´Ù.

ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Áö¿ªÀû À¯Åë È®´ë, ¸ÂÃãÇü ŰƮ Á¦°ø, ½ÉÀå ¼ö¼ú ÆÀ¿¡ ´ëÇÑ ±³À° ¹× Àåºñ Áö¿ø °³¼± µîÀ» ÅëÇØ ÀÌ·¯ÇÑ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ³»±¸¼ºÀÌ ¶Ù¾î³­ ¼öº¹Àû °³ÀÔ°ú °¡´ÉÇÑ °æ¿ì ±³Ã¼ ¼ö¼úº¸´Ù ¿Ü°úÀû ¼öº¹¿¡ ¿ì¼±¼øÀ§¸¦ µÎ´Â °¡¿îµ¥, ¹Ì·¡ÀÇ ±â¼ú Çõ½ÅÀ» Çü¼ºÇÒ °áÁ¤ÀûÀÎ Áú¹®ÀÌ ÀÖ½À´Ï´Ù. ½ÉÀå ÆÇ¸·Áõ °ü¸®ÀÇ ÀÓ»óÀû, °æÁ¦Àû, ÇØºÎÇÐÀû ¿ä±¸»çÇ×ÀÌ ÁøÈ­ÇÏ´Â °¡¿îµ¥, ½ÉÀå ÆÇ¸·Áõ Ä¡·á ±â¼úÀÌ ¼ö¼úÀÇ Á¤È®¼º, Áý´Ü °£ ´Ù¾ç¼º, ¼öº¹ÀÇ ³»±¸¼ºÀ» Áö¼ÓÀûÀ¸·Î Á¦°øÇÒ ¼ö Àִ°¡?

ºÎ¹®

À¯Çü(È®ÀåÇü ½ÉÀå ÆÇ¸·Àý°³µµ, Over the Wire ½ÉÀå ÆÇ¸·Àý°³µµ), ½Ã¼ú À¯Çü(ÆÇ¸·Àý°³¼ú, ½Â¸ðÆÇ ±³·Ã Àý°³¼ú, ±âŸ ½Ã¼ú À¯Çü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø & Ŭ¸®´Ð, ½ÉÀå¿Ü°ú ¼¾ÅÍ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ ÇÕ°è 42»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cardiac Valvulotome Market to Reach US$141.0 Million by 2030

The global market for Cardiac Valvulotome estimated at US$115.0 Million in the year 2024, is expected to reach US$141.0 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Expandable Cardiac Valvulotome, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$89.4 Million by the end of the analysis period. Growth in the Over the Wire Cardiac Valvulotome segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.3 Million While China is Forecast to Grow at 6.6% CAGR

The Cardiac Valvulotome market in the U.S. is estimated at US$31.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$28.4 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Cardiac Valvulotome Market - Key Trends & Drivers Summarized

Why Are Cardiac Valvulotomes Gaining Renewed Relevance in the Surgical Management of Valvular Heart Disease?

Cardiac valvulotomes are critical surgical instruments used to excise or incise fused or thickened heart valve leaflets-primarily in procedures involving valvulotomy or valvuloplasty. These devices are most commonly employed in the treatment of rheumatic or congenital valvular stenosis, where restoring valve function without full replacement is clinically advantageous. As global cardiovascular disease rates rise, particularly in emerging markets where rheumatic heart disease (RHD) remains endemic, cardiac valvulotomes are seeing renewed relevance in surgical practice.

Their utility is especially pronounced in mitral valve stenosis, often in younger patients or regions with limited access to transcatheter valve technologies. By preserving native valve structures and maintaining hemodynamic function, valvulotomes offer a viable, cost-effective option for open-heart surgical centers prioritizing valve repair over replacement-supporting better long-term outcomes and reduced prosthetic complications in select patient populations.

How Are Device Improvements and Surgical Advancements Enhancing Valvulotome Precision and Clinical Outcomes?

Advancements in valvulotome design are focused on improving surgical control, precision, and anatomical adaptability. Modern devices feature sharpened, fine-tipped blades, enhanced grip ergonomics, and variable sizing to accommodate diverse valve morphologies. Innovations such as expandable or retractable blade configurations are allowing more targeted leaflet separation while minimizing trauma to surrounding cardiac tissue.

Minimally invasive cardiac surgery (MICS) techniques, along with improved intraoperative imaging and valve mapping, are increasing the precision of valvulotome use in valve-sparing procedures. These developments support more conservative surgical approaches in patients with early-stage valvular disease or in cases where prosthetic implantation is contraindicated. Additionally, the growing use of hybrid ORs is enabling better integration of surgical tools like valvulotomes with real-time transesophageal echocardiography (TEE) and fluoroscopic guidance.

Where Is Demand for Cardiac Valvulotomes Concentrated and Which Patient Populations Are Driving Usage?

Demand is highest in Asia-Pacific, Africa, and Latin America-regions where RHD prevalence remains significant and access to advanced transcatheter procedures is limited. India, sub-Saharan Africa, Southeast Asia, and parts of South America represent key markets where open-heart surgical interventions are more common in younger RHD patients who benefit from valve-sparing strategies.

Patient populations primarily include individuals with rheumatic mitral stenosis, congenital valvular anomalies, or calcific disease where leaflet fusion can be surgically corrected. Pediatric and adolescent cardiac surgery programs are also driving demand for precision valvulotome instruments tailored for small anatomical structures. Additionally, certain tertiary care centers in developed markets still utilize valvulotomes in select cases where durable repair is preferable to prosthetic valve implantation-particularly in low-risk surgical candidates or valve-conserving protocols.

What Is Fueling the Global Growth of the Cardiac Valvulotome Market?

The cardiac valvulotome market is growing due to the ongoing burden of valvular heart disease, surgical preference for native valve preservation, and continued demand for cost-effective cardiovascular tools in emerging healthcare systems. With rheumatic heart disease still a major contributor to global valve surgeries, valvulotomes remain indispensable instruments in the armamentarium of cardiac surgeons-especially in health systems constrained by affordability and infrastructure limitations.

Medical device manufacturers are supporting this growth by expanding geographic distribution, offering customizable kits, and improving training and instrumentation support for cardiac surgical teams. As health systems prioritize durable, restorative interventions and surgical repair over replacement where feasible, a defining question shapes future innovation: Can cardiac valvulotome technologies continue to deliver surgical precision, cross-population versatility, and repair durability-while aligning with the evolving clinical, economic, and anatomical demands of global valvular disease management?

SCOPE OF STUDY:

The report analyzes the Cardiac Valvulotome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Expandable Cardiac Valvulotome, Over the Wire Cardiac Valvulotome); Procedure Type (Valvulotomy, Mitral Valve Commissurotomy, Other Procedure Types); End-Use (Hospitals & Clinics, Cardiac Surgery Centers, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â